Pages that link to "Q38905860"

The following pages link to Imatinib in systemic mastocytosis: a phase IV clinical trial in patients lacking exon 17 KIT mutations and review of the literature. (Q38905860):

Displaying 11 items.

• Advances in the Classification and Treatment of Mastocytosis: Current Status and Outlook toward the Future. (Q34552564) (← links)
• Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts (Q38777126) (← links)
• Targeted Treatment Options in Mastocytosis (Q41061871) (← links)
• The clinical and molecular diversity of mast cell leukemia with or without associated hematologic neoplasm (Q42234623) (← links)
• Comparative oncology: The paradigmatic example of canine and human mast cell neoplasms (Q57174064) (← links)
• Preclinical human models and emerging therapeutics for advanced systemic mastocytosis (Q59810100) (← links)
• The new tool "" in advanced systemic mastocytosis (Q64042239) (← links)
• Bone Marrow Mast Cell Antibody-Targetable Cell Surface Protein Expression Profiles in Systemic Mastocytosis (Q64277635) (← links)
• Applying Quality by Design Principles in the Development and Preparation of a New Radiopharmaceutical: Technetium-99m-Imatinib Mesylate (Q90579736) (← links)
• Multidisciplinary Challenges in Mastocytosis and How to Address with Personalized Medicine Approaches (Q92879483) (← links)
• Systemic Mastocytosis: Following the Tyrosine Kinase Inhibition Roadmap (Q94453146) (← links)